




Amarin Corporation plc
Investor Relations Department
2 Pembroke House, Upper
Pembroke
Street 28-32
Dublin 2
Ireland

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: AMRN

| | |
|---------------|---|
| Last Trade: | 3.70 |
| Trade Time: | 4:00 PM ET Feb 23, 2018 |
| Change: | 0.03  (+0.817%) |
| Day Range | 3.63 - 3.72 |
| 52-Week Range | 2.85 - 4.60 |
| Volume | 898,327 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Feb 20, 2018

[Amarin to Report Fourth Quarter and Full Year 2017 Results and Host Conference Call on February 27th, 2018](#)

Jan 30, 2018

[Amarin Prices Public Offering of American Depositary Shares](#)

Jan 29, 2018

[Amarin Announces Proposed Public Offering of American Depositary Shares](#)

Jan 23, 2018

[Amarin's REDUCE-IT Cardiovascular Outcomes Study Reaches 90% Mark for Reported Primary Events](#)

Jan 17, 2018

[Amarin Announces Commencement of VASCEPA® Clinical Development in Mainland China](#)

Upcoming Events [\[View all \]](#)

Feb 27, 2018 8:00 AM ET

[Amarin Q4 Results Conference Call](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Mar 1, 2017

[Annual Report \(10-K\)](#)

Apr 21, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 1, 2017

[Quarterly Report \(10-Q\)](#)

Aug 2, 2017

[Quarterly Report \(10-Q\)](#)

May 3, 2017

[Quarterly Report \(10-Q\)](#)